Corrigendum to: Curculigoside promotes osteogenic differentiation of bone marrow stromal cells from ovariectomized rats: Effects of curculigoside on bone (Journal of Pharmacy and Pharmacology, (2013), 65, 7, (1005-1013), 10.1111/jphp.12054);Curculigoside promotes osteogenic differentiation of bone marrow stromal cells from ovariectomized rats

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 7, 2013, Pages 1005-1013

  Shen, Qingping ^a   Zeng, Deliang ^a,b   Zhou, Yong ^a   Xia, Lunguo ^a   Zhao, Yanfan ^a,b   Qiao, Guangyang ^a   Xu, Lianyi ^a,b   Liu, Yan ^a,b   Zhu, Ziyuan ^b   Jiang, Xinquan ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

bone marrow stromal cells; curculigoside; osteoporosis; ovariectomized rats

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; CURCULIGOSIDE; OSTEOCALCIN; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE GENE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; NONHUMAN; OSTEOBLAST; OSTEOCALCIN GENE; OSTEOPROTEGERIN GENE; OVARIECTOMY; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RUNT RELATED TRANSCRIPTION FACTOR 2 GENE; STROMA CELL; TYPE I COLLAGEN GENE;

EID: 84878775362     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.13253     Document Type: Erratum

References (35)

1. Simon LS,. Osteoporosis. Rheum Dis Clin N Am 2007; 33: 149-176.
2. Riggs BL, Melton LJ,. Involutional osteoporosis. New Engl J Med 1986; 314: 1676-1686.
3. Andersen SJ,. Osteoporosis in the older woman. Clin Obstet Gynecol 2007; 50: 752-766.
4. Canalis H, et al. Growth factors and the regulation on bone remodeling. J Clin Invest 1998; 81: 277-281.
5. Termine JD, Wong M,. Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health. Maturitas 1998; 30: 241-245.
6. Cao DP, et al. Curculigo orchioides, a traditional Chinese medicinal plant, prevents bone loss in ovariectomized rats. Maturitas 2008; 59: 373-380.
7. Vijayanarayana K, et al. Evaluation of estrogenic activity of alcoholic extract of rhizomes of Curculigo orchioides. J Ethnopharmacol 2007; 114: 241-245.
8. Pharmacopoeia Commission of the People's Republic of China. Pharmacopoeia of People's Republic of China. Part 1. Chemical Industry Press: Beijing, 2005.
9. Kubo M, et al. A new phenolic glucoside, curculigoside from rhizomes of Curculigo orchioides. Planta Med 1983; 47: 52-55.
10. Harada S, Rodan GA,. Control of osteoblast function and regulation of bone mass. Nature 2003; 423: 349-355.
11. Goltzman D,. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 2002; 1: 784-796.
12. Zhou H, et al. Enhanced bioactivity of bone morphogenetic protein-2 with low dose of 2-N, 6-O-sulfated chitosan in vitro and in vivo. Biomaterials 2009; 30: 1715-1724.
13. Fu LJ, et al. Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation. Bone 2008; 43: 40-47.
14. Jiang XQ, et al. Maxillary sinus floor elevation using a tissue-engineered bone complex with beta-TCP and BMP-2 gene-modified bMSCs in rabbits. Clin Oral Implants Res 2009; 20: 1333-1340.
15. Dempster DW, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846-1853.
16. Ma C, et al. Up-regulation of VEGF by MC3T3-E1 cells treated with curculigoside. Phytother Res 2011; 25: 922-926.
17. Jiao L, et al. Antiosteoporotic activity of phenolic compounds from Curculigo orchioides. Phytomedicine 2009; 16: 874-881.
18. Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
19. Jaiswal RK, et al. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J Biol Chem 2000; 275: 9645-9652.
20. Barbara W, et al. Ascorbic acid enhances adipogenesis of bone marrow-derived mesenchymal stromal cells. Cells Tissues Organs 2009; 189: 373-381.
21. Sun J, et al. Conditioned medium from bone marrow mesenchymal stem cells transiently retards osteoblast differentiation by downregulating Runx2. Cells Tissues Organs 2012; 196: 510-522.
22. Xia LG, et al. Maxillary sinus floor elevation using a tissue-engineered bone with rhBMP-2-Loaded porous calcium phosphate cement scaffold and bone marrow stromal cells in rabbits. Cells Tissues Organs 2011; 194: 481-493.
23. Mathew V, et al. Osteogenic response of bone marrow stromal cells from normal and ovariectomized rats treated with a low dose of basic fibroblast growth factor. Tissue Eng 2007; 13: 809-817.
24. Tanimoto K, et al. Amelogenin enhances the osteogenic differentiation of mesenchymal stem cells derived from bone marrow. Cells Tissues Organs 2012; 196: 411-419.
25. Takayoshi Y, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE 2008; 3: e2615.
26. McCarthy HS, et al. Platelet-derived growth factor stimulates osteoprotegerin production in osteoblastic cells. J Cell Physiol 2009; 218: 350-354.
27. Food and Drug Administration. Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention Or Treatment of Postmenopausal Osteoporosis. Rockville, MD: FDA, 1994.
28. Saka A, et al. Bone marrow cell development and trabecular bone dynamics after ovariectomy in ddy Mice. Bone 1998; 23: 443-451.
29. Rodan GA, Martin TJ,. Therapeutic approaches to bone diseases. Science 2000; 289: 1508-1514.
30. Tang CH, et al. Water solution of onion crude powder inhibits RANKL-induced osteoclastogenesis through ERK, p38 and NF-kappaB pathways. Osteoporos Int 2009; 20: 93-103.
31. Rogers MJ,. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004; 75: 451-461.
32. Knabe C, et al. The effect of bioactive glass ceramics on the expression of bone-related genes and proteins in vitro. Clin Oral Implants Res 2005; 16: 119-127.
33. Komori T, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 30: 755-764.
34. Emery JG, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
35. Humphrey EL, et al. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006; 38: 652-661.